Skip to content

SiriusPoint SPNT Other Specialties — Year 8

Other product segments

Casualty
3.8%+245%
Property Catastrophe
2.5%-13.8%
Property Other
1.1%0.0%
Other
0.2%-75.0%
A&H
-0.1%0.0%

Similar metrics at other companies

Arch Capital Group logo
ACGLSpecialty — Year Eight
0.5%-0.2pp
Arch Capital Group logo
ACGLMulti-line and other specialty — Year Eight
1.4%+0.3pp
Arch Capital Group logo
ACGLSpecialty — Year Seven
1.2%-0.4pp
White Mountains Insurance Group logo
WTMSpecialty — 8
1.8%0.0pp
Arch Capital Group logo
ACGLSpecialty — Year Nine
0%
CNA Financial logo
CNASpecialty — Other
$0

Other financials

Income statement

See full
Revenue$774.6M+6.5%
Net income$102.2M+65.9%
EPS (diluted)$0.82+67.3%

Balance sheet

See full
Cash & equivalents$1.0B+9.2%
Total debt$702.9M+2.2%
Total equity$2.3B+13.7%
Total assets$12.5B+1.6%

Cash flow

See full
Operating cash flow$141.9M+260%

Valuation

See full
Market cap$2.78B+25.6%
Enterprise value$2.47B+25.1%
P/E5.6×-6.5×
P/S0.9×0.0×

Profitability

See full
Net margin15.4%+8.4pp

Returns & leverage

See full
Return on equity23.1%+15.2pp
Debt / equity0.3×0.0×

Where this comes from

Reported directly by SiriusPoint in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearEight.

The official record: SiriusPoint’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about SiriusPoint's other specialties — year 8.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SiriusPoint's other specialties — year 8?
SiriusPoint (SPNT) reported other specialties — year 8 of 0.3% in Q4 2025.
What does other specialties — year 8 mean?
This metric captures the financial results of the Other Specialties segment for the eighth year, serving as a benchmark for the company's specialized underwriting success. It illustrates the segment's contribution to the overall business mix and its resilience within the broader insurance market. Investors utilize this to gauge the maturity and scalability of the company's specialty product portfolio.